Core Viewpoint - Fujian Pharmaceutical Co., Ltd. has experienced significant stock price increases this year, with a 120.14% rise year-to-date and a 25.93% increase in the last five trading days, indicating strong market interest and potential investment opportunities [1][2]. Financial Performance - For the period from January to September 2025, Fujian Pharmaceutical reported a revenue of 769 million yuan, a year-on-year decrease of 21.24%, and a net profit attributable to shareholders of -62.75 million yuan, a slight decrease of 1.09% [2]. - The company has cumulatively distributed 359 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of November 19, the stock price reached 18.36 yuan per share, with a trading volume of 502 million yuan and a turnover rate of 6.20%, resulting in a total market capitalization of 9.89 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on November 17, where it recorded a net buy of -40.63 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 7.87% to 20,700, while the average circulating shares per person increased by 5.59% to 21,347 shares [2].

Company Overview - Harbin Sanlian Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, established on June 21, 1996, and listed on September 22, 2017. The company specializes in the research, production, and sales of chemical drug formulations [1][2]. Financial Performance - As of November 10, 2023, Harbin Sanlian reported a revenue of 581 million yuan for the period from January to September 2025, a year-on-year decrease of 30.75%. The net profit attributable to the parent company was -209 million yuan, a significant decline of 614.61% [2]. - The company has cumulatively distributed 677 million yuan in dividends since its A-share listing, with 158 million yuan distributed over the past three years [3]. Stock Performance - On November 18, 2023, Harbin Sanlian's stock price increased by 2.34%, reaching 14.89 yuan per share, with a trading volume of 52.42 million yuan and a turnover rate of 2.05%. The total market capitalization stood at 4.711 billion yuan [1]. - Year-to-date, the stock price has risen by 54.30%, with a 2.69% increase over the last five trading days and a 12.12% increase over the last 20 days. However, it has seen a decline of 1.72% over the past 60 days [1]. Shareholder Information - As of November 10, 2023, the number of shareholders for Harbin Sanlian was 39,600, a decrease of 2.98% from the previous period. The average number of circulating shares per person increased by 3.07% to 4,419 shares [2]. Business Segmentation - The main revenue sources for Harbin Sanlian include: large-volume injections (32.00%), lyophilized powder injections (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and other segments such as veterinary drugs (2.55%) and import/export trade (1.82%) [1].

11月17日，通化金马盘中上涨2.23%，截至11:05，报29.39元/股，成交3.93亿元，换手率1.41%，总市值 284.05亿元。 资金流向方面，主力资金净流出1759.63万元，特大单买入2862.41万元，占比7.28%，卖出4253.98万 元，占比10.82%；大单买入1.15亿元，占比29.36%，卖出1.19亿元，占比30.29%。 通化金马所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：民营医院、工业大麻、 东北振兴、肝炎治疗、中药等。 截至9月30日，通化金马股东户数3.82万，较上期减少3.20%；人均流通股25266股，较上期增加3.31%。 2025年1月-9月，通化金马实现营业收入8.92亿元，同比减少7.88%；归母净利润2496.35万元，同比增长 4.35%。 分红方面，通化金马A股上市后累计派现2.10亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，通化金马十大流通股东中，创新药（159992）位居第七大流通股 东，持股919.30万股，相比上期增加8.78万股。南方中证1000ETF（512100）位居第八大流通股东，持 ...

11月17日，安科生物盘中下跌2.03%，截至10:04，报10.61元/股，成交1.13亿元，换手率0.86%，总市值 177.45亿元。 安科生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：民营医院、基因测 序、互联医疗、医疗美容、肝炎治疗等。 截至10月31日，安科生物股东户数7.69万，较上期增加4.63%；人均流通股15886股，较上期减少 4.43%。2025年1月-9月，安科生物实现营业收入19.63亿元，同比增长2.15%；归母净利润5.51亿元，同 比减少6.48%。 分红方面，安科生物A股上市后累计派现26.62亿元。近三年，累计派现12.52亿元。 机构持仓方面，截止2025年9月30日，安科生物十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1952.26万股，相比上期减少126.90万股。招商国证生物医药指数A（161726）位居第五大 流通股东，持股1596.17万股，相比上期减少273.29万股。创新药（159992）位居第七大流通股东，持股 1121.77万股，相比上期增加19.13万股。南方中证1000ETF（512100）位居第九大流通 ...

博济医药所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：幽门螺杆概念、肝 炎治疗、中药、小盘、多肽药等。 11月13日，博济医药盘中上涨2.19%，截至13:09，报10.74元/股，成交1.31亿元，换手率4.45%，总市值 41.43亿元。 资金流向方面，主力资金净流出92.84万元，特大单买入523.74万元，占比4.00%，卖出629.01万元，占 比4.81%；大单买入1706.09万元，占比13.04%，卖出1693.66万元，占比12.94%。 博济医药今年以来股价涨23.19%，近5个交易日涨7.51%，近20日涨9.15%，近60日跌4.11%。 资料显示，博济医药科技股份有限公司位于广东省广州市天河区华观路1933号万科云广场A栋7楼，成 立日期2002年9月29日，上市日期2015年4月24日，公司主营业务涉及为医药企业和其他新药研发机构的 新药研发提供临床前研究服务、临床研究服务、技术成果转化服务以及与新药研发有关的其他咨询服务 等,协助客户快速、高效地完成新药研发的各个阶段。主营业务收入构成为：临床研究服务80.18%，临 床前研究服务11.31%，其他咨询服务6 ...

Company Overview - Pursuit Pharmaceutical Technology Co., Ltd. is located at 500 Guangdong Road, World Trade Building, 23rd Floor, Huangpu District, Shanghai, established on February 22, 2013, and listed on May 17, 2022 [1] - The company specializes in technology development, transfer, consulting, and services within the pharmaceutical sector, with 100% of its revenue derived from service activities [1] Financial Performance - For the period from January to September 2025, Pursuit achieved a revenue of 609 million yuan, representing a year-on-year growth of 2.59%, and a net profit attributable to shareholders of 87.38 million yuan, up 20.92% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 40.77 million yuan [3] Stock Performance - As of November 12, the stock price of Pursuit was 45.88 yuan per share, with a market capitalization of 3.625 billion yuan [1] - The stock has increased by 70.81% year-to-date, but has seen a decline of 6.04% over the last five trading days [1] Shareholder Information - As of October 31, the number of shareholders was 8,576, a decrease of 0.14% from the previous period, with an average of 8,782 circulating shares per shareholder, an increase of 0.14% [2] - Notable shareholders include Noan Pioneer Mixed A (320003) as the fifth largest shareholder with 3.29 million shares, and Tianhong Medical Health A (001558) as the eighth largest shareholder with 961,000 shares, which decreased by 467,700 shares from the previous period [3] Market Activity - On November 12, the stock experienced a trading volume of 57.36 million yuan, with a turnover rate of 1.63% [1] - The net inflow of main funds was 1.08 million yuan, with large orders accounting for 16.99% of purchases and 15.11% of sales [1] Industry Classification - Pursuit is classified under the Shenwan industry as part of the pharmaceutical and biological sector, specifically in medical services and medical research outsourcing [1] - The company is associated with various concept sectors including margin financing, buybacks, small-cap stocks, hepatitis treatment, and medical devices [1]

Core Viewpoint - The stock of Zhifei Biological has shown fluctuations, with a recent increase of 2.04% but a year-to-date decline of 16.50%, indicating potential volatility in the market [1][2]. Company Overview - Zhifei Biological, established on July 20, 1995, and listed on September 28, 2010, is located in Chongqing and specializes in the research, production, and sales of vaccines and biological products [1]. - The company's revenue composition includes 88.84% from agency products, 10.15% from self-developed products, and 1.00% from other sources [1]. Financial Performance - For the period from January to September 2025, Zhifei Biological reported a revenue of 76.27 billion, a year-on-year decrease of 66.53%, and a net profit attributable to shareholders of -12.06 billion, reflecting a significant decline of 156.10% [2]. - Cumulatively, the company has distributed 73.18 billion in dividends since its A-share listing, with 31.94 billion distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Zhifei Biological is 131,600, a decrease of 3.17% from the previous period, with an average of 10,750 circulating shares per shareholder, an increase of 3.28% [2]. - The top ten circulating shareholders include significant institutional investors, with notable reductions in holdings for several funds, indicating potential shifts in investor sentiment [3].

Core Viewpoint - The stock of Zhifei Biological has shown fluctuations, with a recent increase of 2.02% and a year-to-date decline of 19.32%, indicating potential volatility in the market [1][2]. Company Overview - Zhifei Biological, established on July 20, 1995, and listed on September 28, 2010, is based in Chongqing and specializes in the research, production, and sales of vaccines and biological products [1]. - The company's revenue composition includes 88.84% from agency products, 10.15% from self-developed products, and 1.00% from other sources [1]. Financial Performance - For the period from January to September 2025, Zhifei Biological reported a revenue of 7.627 billion yuan, a year-on-year decrease of 66.53%, and a net profit attributable to shareholders of -1.206 billion yuan, a decline of 156.10% [2]. - Cumulatively, the company has distributed 7.318 billion yuan in dividends since its A-share listing, with 3.194 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Zhifei Biological was 131,600, a decrease of 3.17% from the previous period, with an average of 10,750 shares held per shareholder, an increase of 3.28% [2]. - The top ten circulating shareholders include significant institutional investors, with notable reductions in holdings for several funds, indicating potential shifts in investor sentiment [3].

Core Viewpoint - Xinhua Pharmaceutical's stock has shown a modest increase in recent trading sessions, with a year-to-date rise of 5.05%, despite a decline over the past 60 days [1][2]. Group 1: Stock Performance - On November 7, Xinhua Pharmaceutical's stock rose by 2.33%, reaching 16.24 CNY per share, with a trading volume of 1.20 billion CNY and a turnover rate of 1.52% [1]. - The stock has experienced a net inflow of 620.05 thousand CNY from major funds, with significant buying activity from large orders [1]. - Year-to-date, the stock has appeared on the "Dragon and Tiger List" once, with a net purchase of 15.67 million CNY on January 6 [1]. Group 2: Financial Performance - For the period from January to September 2025, Xinhua Pharmaceutical reported a revenue of 6.763 billion CNY, reflecting a year-on-year growth of 0.42%, while the net profit attributable to shareholders decreased by 25.53% to 256 million CNY [2]. - Cumulative cash dividends since the A-share listing amount to 1.17 billion CNY, with 495 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 7.60% to 70,700, with an average of 0 circulating shares per person [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several ETFs, all of which have seen a reduction in their holdings compared to the previous period [3].

Core Viewpoint - Anke Biological has shown a mixed performance in stock price and financial results, with a notable increase in stock price year-to-date but a decline in net profit for the recent period [1][2]. Financial Performance - As of October 31, Anke Biological reported a revenue of 1.963 billion yuan for the period from January to September 2025, representing a year-on-year growth of 2.15%. However, the net profit attributable to shareholders was 551 million yuan, which reflects a decrease of 6.48% compared to the previous year [2]. - The company has cumulatively distributed 2.662 billion yuan in dividends since its A-share listing, with 1.252 billion yuan distributed over the last three years [3]. Stock Market Activity - On November 7, Anke Biological's stock price increased by 2.06%, reaching 10.91 yuan per share, with a trading volume of approximately 90.89 million yuan and a turnover rate of 0.69%. The total market capitalization stood at 18.247 billion yuan [1]. - Year-to-date, the stock price has risen by 30.02%, with a slight increase of 5.72% over the past 20 trading days [1]. Shareholder Structure - As of September 30, 2025, Anke Biological had 76,900 shareholders, an increase of 4.63% from the previous period. The average number of circulating shares per shareholder decreased by 4.43% to 15,886 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 19.5226 million shares, a decrease of 1.269 million shares from the previous period [3].